
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor-? (FR?) and ZW171, a bispecific 2 + …